Precipio, Inc., a healthcare solutions company, provides diagnostic products, reagents, and services in the United States. It provides diagnostic blood cancer testing services. The company offers IV-Cell, a proprietary cell culture media that enables simultaneous culturing of four hematopoietic cell lineages; HemeScreen, a suite of robust genetic diagnostic panels; ICE-COLD PCR, a proprietary and patented specimen technology that increases the sensitivity of molecular based tests; and COVID-19 antibody tests. It sells ICE-COLD-PCR technology kits to bio-pharma customers. Precipio, Inc. has collaborations with academic institutions specializing in cancer research, diagnostics, and treatment. The company is based in New Haven, Connecticut.
P/E ratio for Precipio, Inc. (PRPO)
P/E ratio as of 2023: -1.44
According to Precipio, Inc.'s latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -1.44. At the end of 2022 the company had a P/E ratio of -1.03.
P/E ratio history for Precipio, Inc. from 1999 to 2023
PE ratio at the end of each year
| Year | P/E ratio |
|---|---|
| 2023 | -1.44 |
| 2022 | -1.03 |
| 2021 | -3.90 |
| 2020 | -2.79 |
| 2019 | -0.88 |
| 2018 | -0.21 |
| 2017 | -0.27 |
| 2016 | -0.02 |
| 2015 | -0.11 |
| 2014 | -3.22 |
| 2013 | -2.73 |
| 2012 | -4.18 |
| 2011 | -2.52 |
| 2010 | -7.86 |
| 2009 | -12.81 |
| 2008 | -49.69 |
| 2007 | -11.67 |
| 2006 | -7.17 |
| 2005 | -1.19 |
| 2004 | -0.42 |
| 2003 | -0.53 |
| 2002 | -0.55 |
| 2001 | -1.52 |
| 2000 | -0.96 |
| 1999 | -0.66 |